ZyVersa Therapeutics Inc. Market Cap ($866.26K)
Market Cap & Net Worth: ZyVersa Therapeutics Inc. (ZVSA)
ZyVersa Therapeutics Inc. market cap. ZyVersa Therapeutics Inc. (NASDAQ:ZVSA) has a market capitalization of $866.26K ($866.26K) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30778 globally and #6256 in its home market, demonstrating a 7.86% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ZyVersa Therapeutics Inc.'s stock price $0.11 by its total outstanding shares 8095921 (8.10 Million). Also see ZVSA cash generation efficiency for how efficiently the company converts equity into cash flow.
ZyVersa Therapeutics Inc. Market Cap History (2022–2026)
ZyVersa Therapeutics Inc. market cap history from 2022 to 2026. Data shows growth from $4.45 Billion to $866.26K (33.78% CAGR). Check ZyVersa Therapeutics Inc. stock price for real-time trading data and today's change.
Index Memberships
ZyVersa Therapeutics Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #899 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #2854 of 3165 |
Weight: ZyVersa Therapeutics Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ZyVersa Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ZyVersa Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of ZyVersa Therapeutics Inc. to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ZVSA by Market Capitalization
Companies near ZyVersa Therapeutics Inc. in the global market cap rankings as of November 1, 2026. Also see ZyVersa Therapeutics Inc. total assets for a full breakdown of the balance sheet.
Key companies related to ZyVersa Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of ZyVersa Therapeutics Inc. (2022–2026)
Market capitalization of ZyVersa Therapeutics Inc. from 2022 to today. Between 2022 and today, ZyVersa Therapeutics Inc.'s market cap moved from $4.45 Billion to $ 866.26K, with a yearly change of 33.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $866.26K | -19.73% |
| 2025 | $1.08 Million | -87.54% |
| 2024 | $8.66 Million | -88.11% |
| 2023 | $72.86 Million | -98.36% |
| 2022 | $4.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 1st, 2026 the market cap of ZyVersa Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $866.26K USD |
| MoneyControl | $866.26K USD |
| MarketWatch | $866.26K USD |
| marketcap.company | $866.26K USD |
| Reuters | $866.26K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ZyVersa Therapeutics Inc.
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glome… Read more